Volume 29, No 11, Nov 2019

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 29 Issue 11, November 2019: 875-876

RESEARCH HIGHLIGHTS

Halting triple negative breast cancer by targeting PROCR

Nai Yang Fu¹ and Jane E. Visvader ^2,3

¹ Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore 169857, Singapore; ²Cancer Biology and Stem Cells Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia and ³Department of Medical Biology, The University of Melbourne, Parkville, VIC 3010, Australia
Correspondence: Jane E. Visvader (visvader@wehi.edu.au)

Cancer stem cells (CSCs) achieved prominence as a concept to explain the inexorable growth of cancers, but the paucity of robust CSC markers for solid tumors has seen the field wane in recent years. Wang et al. now report that a cell surface protein PROCR (Protein C Receptor) enriches for CSCs in about half of triple negative breast cancers and show that inhibition of receptor function by a nanobody profoundly decreases tumor growth, thus highlighting PROCR as a potential therapeutic target.

https://doi.org/10.1038/s41422-019-0245-5

FULL TEXT | PDF

Browse 666